FEMY · Femasys Inc.

Femasys Inc. reported full-year 2025 financial results showing revenue growth of 40.8% to $2.3 million, primarily from FemBloc sales, reflecting progress in commercialization efforts. Gross costs rose with sales volume, but R&D expenses declined 7.8% to $7.6 million due to shifting development products into inventory, lower professional fees, and compensation, though offset by higher regulatory costs. Operating expenses increased slightly to $19.0 million, driven by sales and marketing and G&A growth. The net loss narrowed marginally to $18.6 million or ($0.47) per share from $18.8 million or ($0.85) per share in 2024, aided by non-cash gains from changes in fair value of conversion option and warrants liabilities totaling $1.2 million, partially offset by higher interest expense. Balance sheet strengthened with cash rising to $9.3 million from $3.5 million, supported by a $12 million financing, enabling operations into Q3 2026. Inventory doubled to $5.7 million, signaling commercial ramp-up. Corporate highlights include FINALE trial enrollment for FemBloc U.S. approval, MDSAP certification, CPT code approval for FemaSeed, FDA clearance for FemVue, and partnerships in Switzerland and with Refuah Health. CEO Kathy Lee-Sepsick emphasized expanding FemaSeed with FemSperm and advancing FemBloc, positioning the company to address reproductive health gaps with in-office solutions.